1. Scrip
  2. >>Business
  3. >>Earnings

Pharma Is Priority As GSK Confirms Split With Consumer

Break-Up By July 2022

 
• By Kevin Grogan

With CEO Emma Walmsley determined to keep investing in new technologies, GlaxoSmithKline has launched a two-year program to prepare for the separation of its pharma and consumer healthcare units into two companies.

Model_Train_Track
GSK To Split into two • Source: Shutterstock

GlaxoSmithKline PLC has begun its two-year program to split into two, creating a consumer healthcare standalone and a "biopharma company focused on science related to the immune system, use of genetics and new technologies."

There had been some conflicting messages of late regarding the future of the consumer business which GSK operates as a joint venture with Pfizer since a deal that closed at the end of July last year. At the J.P. Morgan Healthcare Conference in January, Pfizer CEO Albert Bourla said he believed the JV was moving towards an initial public offering within three to four years but GSK, which has majority ownership (68%) of the JV, also has control of the separation and is looking to move faster

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By Andy Smith

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Takeda Plans US Investment But Sees Little Impact From Tariffs

 
• By Alaric DeArment

The Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.

More from Business

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Roche Reveals Another US Manufacturing Site As Tariff Pressures Seem To Ease

 
• By Mandy Jackson

Roche/Genentech unveiled plans for a $700m-plus manufacturing facility for weight loss drugs in North Carolina as President Trump signaled such investments could mean no tariffs for pharma.

Trump’s MFN Executive Order More Rhetoric Than Action

 
• By Jessica Merrill

The details of Trump’s latest executive order on drug pricing are vague and the president put more blame on other countries and pharma distributors than drug companies.